WILLIAM R. LOCKWOOD, M.D.; JOHN F. BUSEY, M.D.; BLAIR E. BATSON, M.D.; FRED ALLISON JR., M.D.
The dramatic antifungal effect of stilbamidine in control of systemic blastomycosis in human beings, reported by Schoenbach, Miller, Ginsberg, and Long in 1951, represented the first substantial and effective therapy for this disease (1). Their observations were confirmed by others, but a significant incidence of peripheral neuropathy associated with use of the drug led to investigation of other, though structurally similar, agents. Shortly thereafter, 2-hydroxystilbamidine was found to exhibit similar antimycotic properties although it was less active than stilbamidine on a weight basis (2). Furthermore, 2-hydroxystilbamidine was clearly less toxic than stilbamidine and soon replaced it as the treatment of
LOCKWOOD WR, BUSEY JF, BATSON BE, et al. Experiences in the Treatment of North American Blastomycosis with 2-Hydroxystilbamidine. Ann Intern Med. 1962;57:553–562. doi: 10.7326/0003-4819-57-4-553
Download citation file:
Published: Ann Intern Med. 1962;57(4):553-562.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use